Edition:
United Kingdom

Orexigen Therapeutics Inc (OREX.OQ)

OREX.OQ on NASDAQ Stock Exchange Global Select Market

1.20USD
15 Dec 2017
Change (% chg)

$-0.03 (-2.44%)
Prev Close
$1.23
Open
$1.21
Day's High
$1.24
Day's Low
$1.18
Volume
31,157
Avg. Vol
30,679
52-wk High
$5.69
52-wk Low
$1.16

Select another date:

Fri, Dec 1 2017

BRIEF-Man Group Plc Reports 8.54 Pct Passive Stake In Orexigen Therapeutics

* MAN GROUP PLC REPORTS 8.54 PERCENT PASSIVE STAKE IN OREXIGEN THERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING‍​ Source text : http://bit.ly/2AKRpMo Further company coverage:

BRIEF-Orexigen Says Entered Into Exchange Agreements With Holders

* OREXIGEN - ENTERED INTO EXCHANGE AGREEMENTS WITH HOLDERS OF 2.75% CONVERTIBLE EXCHANGE SENIOR NOTES DUE 2020, 2.75% CONVERTIBLE SENIOR NOTES DUE 2020

BRIEF-Orexigen Therapeutics Q3 loss per share $1.35

* Orexigen Therapeutics announces third quarter 2017 financial results

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt

* Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt, Germany for contrave in Latin America

BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co

* Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​

BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030

* Orexigen announces favorable decision from U.S. District Court in patent litigation, confirming exclusivity for Contrave through 2030

BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍​

* Orexigen Therapeutics Inc sees Orexigen net sales $85 million to $100 million for 2017 - presentation slides‍​ Source text: (http://bit.ly/2fpwCRS) Further company coverage:

BRIEF-Orexigen Therapeutics to provide business update

* Orexigen Therapeutics to provide business update at the 2017 Cantor Fitzgerald Global Healthcare Conference Source text for Eikon: Further company coverage:

BRIEF-Orexigen Therapeutics Q2 loss per share $2.00

* Orexigen Therapeutics announces second quarter 2017 financial results

BRIEF-Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

* Orexigen Therapeutics announces commercialization and distributorship arrangement with Cheplapharm Arzneimittel GmbH for Mysimba in Germany, France and Austria

Select another date: